Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?

ABSTRACT: This Practice Point commentary discusses the findings of the first phase I trial to evaluate abiraterone acetate (an inhibitor of the androgen-regulating enzyme CYP17) in the treatment of castration-resistant prostate cancer. This open-label, dose-escalation study by Attard et al. showed that abiraterone was well tolerated but often induced a syndrome of secondary mineralocorticoid excess that improved with eplerenone (a mineralocorticoid receptor antagonist). Abiraterone is a potent suppressor of adrenal androgen synthesis, and produced lasting prostate-specific antigen responses in approximately half of the patients. A few patients had partial regression of distant metastases. Although promising, these results should be interpreted with caution owing to the small sample size and because

SUBMITTER: Antonarakis ES 

PROVIDER: S-EPMC4014058 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature